(0.23%) 5 307.75 points
(0.26%) 38 893 points
(0.30%) 18 647 points
(-0.21%) $76.83
(4.25%) $2.70
(-0.22%) $2 340.60
(-0.92%) $30.16
(0.10%) $1 043.00
(0.02%) $0.921
(0.08%) $10.49
(0.01%) $0.785
(-0.47%) $90.01
Live Chart Being Loaded With Signals
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform...
Stats | |
---|---|
本日の出来高 | 192.00 |
平均出来高 | 0.00 |
時価総額 | 4.03M |
EPS | $-0.317 ( 2023-09-29 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 0 |
ATR14 | $0 (0.00%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-12-22 | Mckee Kelly T. Jr. | Buy | 6 944 | Common Stock |
2023-09-25 | Mckee Kelly T. Jr. | Buy | 9 653 | Common Stock |
2023-08-25 | Dodd David A | Buy | 35 087 | Common Stock |
2023-08-18 | Reynolds Mark | Buy | 10 000 | Common Stock |
2023-08-01 | Spencer John N Jr | Buy | 50 000 | Stock Option |
INSIDER POWER |
---|
99.86 |
Last 95 transactions |
Buy: 15 412 165 | Sell: 50 000 |
GeoVax Labs, Inc. 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
GeoVax Labs, Inc. 財務諸表
Annual | 2023 |
収益: | $0 |
総利益: | $-74 169.00 (0.00 %) |
EPS: | $-14.29 |
FY | 2023 |
収益: | $0 |
総利益: | $-74 169.00 (0.00 %) |
EPS: | $-14.29 |
FY | 2022 |
収益: | $81 000.00 |
総利益: | $24 716.00 (30.51 %) |
EPS: | $-12.39 |
FY | 2021 |
収益: | $385 501 |
総利益: | $0.00 (0.00 %) |
EPS: | $0 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
GeoVax Labs, Inc.
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is also developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; GEO-EM01 for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. GeoVax Labs, Inc. has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。